About: Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Latest price: $76.78 (-2.23%)
DNTH NASDAQ Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. share price
Atividade de preço de DNTH
Último preço
$ 76,780
Variação (24h)
-1,75 USD (2,23%)
Volume
379.06K
Volume (média 4 sem.)
-
Abertura
$ 76,03
Variação do dia
$ 76,03 - $ 78,16
Fechamento anterior
$ 78,53
Último negócio
23 Oct, 8:00 pm GMT+0
Atrasado
23 Oct, 8:00 pm GMT+0
DNTH price performance
Atrasado
23 Oct, 8:00 pm GMT+0
quote.marketSignals